drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified NK cells)
drug_description
Gene-engineered natural killer (NK) cells expressing a chimeric antigen receptor based on NKG2D to recognize stress-inducible ligands (e.g., MICA, MICB, ULBPs) on AML cells and trigger NK cytotoxicity via DAP10/CD3ζ signaling.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Killer Cells, Natural
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene-engineered NK cells expressing an NKG2D-based chimeric antigen receptor recognize stress-inducible ligands (MICA/MICB/ULBPs) on AML cells and signal via DAP10/CD3ζ to activate NK cytotoxicity, leading to perforin/granzyme-mediated killing and cytokine release against leukemic cells.
drug_name
NKG2D CAR-NK cells
nct_id_drug_ref
NCT05734898